Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer

Nicolas Acquavella, Harriet Kluger, John Rhee, Leonard Farber, Harold Tara, Stephan Ariyan, Deepak Narayan, William Kelly, Mario Sznol

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The standard q8h high-dose interleukin-2 (IL-2) regimen produces clear benefit for a subset of patients, but has limited acceptance because of its substantial acute toxicity including hypotension requiring pressors in 30% to 50%, the schedule is inconvenient for medical staff who must assess patients before each dose, and in some hospitals, the limited availability of monitored beds. We initiated a high-dose IL-2 program with a modified twice daily dosing schedule, limited the total number of doses per course to 8, and treated patients in an oncology ward without cardiac monitoring. Hypotension was managed preferentially with normal saline fluid boluses and/or delay in treatment. We conducted a retrospective chart review of 41 consecutive metastatic melanoma (n=33) and renal cancer (n=8) patients treated with the modified high-dose IL-2 regimen. The median number of IL-2 doses administered in the first cycle was 15. Overall toxicity was similar to published data for the q8h schedule, but only 9.79% of patients required pressors. Twenty-four percent of patients were transferred electively or emergently to the intensive care unit. There were no treatment-related deaths. The objective response rate was 12.5% and 0% in melanoma and renal cancer, respectively. Responses were durable, and 2 additional melanoma patients with mixed responses remain disease-free after resection of residual or recurrent sites of disease. In summary, the twicedaily IL-2 regimen has meaningful activity, may be more convenient to administer, reduces the need for elective monitored beds, and may be preferable for development of combinations with newer immune modulators.

Original languageEnglish (US)
Pages (from-to)569-576
Number of pages8
JournalJournal of Immunotherapy
Volume31
Issue number6
DOIs
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Melanoma
Appointments and Schedules
Kidney Neoplasms
Hypotension
Medical Staff
Intensive Care Units
Therapeutics

Keywords

  • High dose
  • Interleukin-2
  • Metastatic melanoma
  • Metastatic renal cancer
  • Toxicity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology

Cite this

Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. / Acquavella, Nicolas; Kluger, Harriet; Rhee, John; Farber, Leonard; Tara, Harold; Ariyan, Stephan; Narayan, Deepak; Kelly, William; Sznol, Mario.

In: Journal of Immunotherapy, Vol. 31, No. 6, 07.2008, p. 569-576.

Research output: Contribution to journalArticle

Acquavella, Nicolas ; Kluger, Harriet ; Rhee, John ; Farber, Leonard ; Tara, Harold ; Ariyan, Stephan ; Narayan, Deepak ; Kelly, William ; Sznol, Mario. / Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. In: Journal of Immunotherapy. 2008 ; Vol. 31, No. 6. pp. 569-576.
@article{c33d80d110c54cf1ae56d550221ce9d1,
title = "Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer",
abstract = "The standard q8h high-dose interleukin-2 (IL-2) regimen produces clear benefit for a subset of patients, but has limited acceptance because of its substantial acute toxicity including hypotension requiring pressors in 30{\%} to 50{\%}, the schedule is inconvenient for medical staff who must assess patients before each dose, and in some hospitals, the limited availability of monitored beds. We initiated a high-dose IL-2 program with a modified twice daily dosing schedule, limited the total number of doses per course to 8, and treated patients in an oncology ward without cardiac monitoring. Hypotension was managed preferentially with normal saline fluid boluses and/or delay in treatment. We conducted a retrospective chart review of 41 consecutive metastatic melanoma (n=33) and renal cancer (n=8) patients treated with the modified high-dose IL-2 regimen. The median number of IL-2 doses administered in the first cycle was 15. Overall toxicity was similar to published data for the q8h schedule, but only 9.79{\%} of patients required pressors. Twenty-four percent of patients were transferred electively or emergently to the intensive care unit. There were no treatment-related deaths. The objective response rate was 12.5{\%} and 0{\%} in melanoma and renal cancer, respectively. Responses were durable, and 2 additional melanoma patients with mixed responses remain disease-free after resection of residual or recurrent sites of disease. In summary, the twicedaily IL-2 regimen has meaningful activity, may be more convenient to administer, reduces the need for elective monitored beds, and may be preferable for development of combinations with newer immune modulators.",
keywords = "High dose, Interleukin-2, Metastatic melanoma, Metastatic renal cancer, Toxicity",
author = "Nicolas Acquavella and Harriet Kluger and John Rhee and Leonard Farber and Harold Tara and Stephan Ariyan and Deepak Narayan and William Kelly and Mario Sznol",
year = "2008",
month = "7",
doi = "10.1097/CJI.0b013e318177a4ba",
language = "English (US)",
volume = "31",
pages = "569--576",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer

AU - Acquavella, Nicolas

AU - Kluger, Harriet

AU - Rhee, John

AU - Farber, Leonard

AU - Tara, Harold

AU - Ariyan, Stephan

AU - Narayan, Deepak

AU - Kelly, William

AU - Sznol, Mario

PY - 2008/7

Y1 - 2008/7

N2 - The standard q8h high-dose interleukin-2 (IL-2) regimen produces clear benefit for a subset of patients, but has limited acceptance because of its substantial acute toxicity including hypotension requiring pressors in 30% to 50%, the schedule is inconvenient for medical staff who must assess patients before each dose, and in some hospitals, the limited availability of monitored beds. We initiated a high-dose IL-2 program with a modified twice daily dosing schedule, limited the total number of doses per course to 8, and treated patients in an oncology ward without cardiac monitoring. Hypotension was managed preferentially with normal saline fluid boluses and/or delay in treatment. We conducted a retrospective chart review of 41 consecutive metastatic melanoma (n=33) and renal cancer (n=8) patients treated with the modified high-dose IL-2 regimen. The median number of IL-2 doses administered in the first cycle was 15. Overall toxicity was similar to published data for the q8h schedule, but only 9.79% of patients required pressors. Twenty-four percent of patients were transferred electively or emergently to the intensive care unit. There were no treatment-related deaths. The objective response rate was 12.5% and 0% in melanoma and renal cancer, respectively. Responses were durable, and 2 additional melanoma patients with mixed responses remain disease-free after resection of residual or recurrent sites of disease. In summary, the twicedaily IL-2 regimen has meaningful activity, may be more convenient to administer, reduces the need for elective monitored beds, and may be preferable for development of combinations with newer immune modulators.

AB - The standard q8h high-dose interleukin-2 (IL-2) regimen produces clear benefit for a subset of patients, but has limited acceptance because of its substantial acute toxicity including hypotension requiring pressors in 30% to 50%, the schedule is inconvenient for medical staff who must assess patients before each dose, and in some hospitals, the limited availability of monitored beds. We initiated a high-dose IL-2 program with a modified twice daily dosing schedule, limited the total number of doses per course to 8, and treated patients in an oncology ward without cardiac monitoring. Hypotension was managed preferentially with normal saline fluid boluses and/or delay in treatment. We conducted a retrospective chart review of 41 consecutive metastatic melanoma (n=33) and renal cancer (n=8) patients treated with the modified high-dose IL-2 regimen. The median number of IL-2 doses administered in the first cycle was 15. Overall toxicity was similar to published data for the q8h schedule, but only 9.79% of patients required pressors. Twenty-four percent of patients were transferred electively or emergently to the intensive care unit. There were no treatment-related deaths. The objective response rate was 12.5% and 0% in melanoma and renal cancer, respectively. Responses were durable, and 2 additional melanoma patients with mixed responses remain disease-free after resection of residual or recurrent sites of disease. In summary, the twicedaily IL-2 regimen has meaningful activity, may be more convenient to administer, reduces the need for elective monitored beds, and may be preferable for development of combinations with newer immune modulators.

KW - High dose

KW - Interleukin-2

KW - Metastatic melanoma

KW - Metastatic renal cancer

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=48549087937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48549087937&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e318177a4ba

DO - 10.1097/CJI.0b013e318177a4ba

M3 - Article

VL - 31

SP - 569

EP - 576

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 6

ER -